Skip to main content
AC Immune SA logo

AC Immune SA — Investor Relations & Filings

Ticker · ACIU ISIN · CH0329023102 LEI · 967600VLQ0ZC2HSOG765 US Manufacturing
Open in API
Filings indexed 285 across all filing types
Latest filing 2026-05-15 Board/Management Inform…
Country CH Switzerland
Listing US ACIU

About AC Immune SA

https://www.acimmune.com/

AC Immune SA is a clinical-stage biopharmaceutical company specializing in precision medicine for neurodegenerative diseases. The company pioneers novel approaches to diagnose, treat, and prevent conditions driven by misfolded proteins, including Alzheimer's disease, Parkinson's disease, and other rare indications. Its diversified pipeline includes therapeutic and diagnostic candidates developed through proprietary technology platforms. These candidates encompass various treatment modalities such as active immunotherapies, antibodies, and small molecules. The company's scientific and clinical strategies are validated through collaboration partnerships with global pharmaceutical leaders.

Recent filings

Filing Released Lang Actions
FORM 6-K
Board/Management Information Classification · 90% confidence The document is a Form 6-K filed by AC Immune SA, but the substantive content focuses on appointments and changes in the company’s senior management and board committees (Interim CEO, Lead Independent Director, Audit & Finance Committee member). This directly matches the “Board/Management Information” category (MANG).
2026-05-15 English
6-K - AC Immune SA (0001651625) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by AC Immune SA announcing the retirement of its CEO at the next AGM and the appointment of an interim CEO. It focuses exclusively on changes in senior management, with no financial statements or other regulatory matters. This fits the “Board/Management Information” category.
2026-05-12 English
6-K - AC Immune SA (0001651625) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to provide updates on financial and corporate matters between annual reports. It includes a press release announcing financial and corporate updates for the first quarter of 2026, but it does not contain detailed financial statements or comprehensive analysis. The document length is short (2187 characters), and it primarily serves as an announcement of updates rather than a full financial report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2026-04-30 English
6-K - AC Immune SA (0001651625) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, AC Immune SA, with the SEC. It contains a press release announcing the initiation of a clinical trial cohort, attached as an exhibit. The document is short (1745 characters) and primarily serves as an announcement of the press release rather than a detailed report or financial statement. There is no substantive financial data or detailed analysis present. According to the rules, such filings that announce or attach reports or press releases without containing the reports themselves should be classified as Regulatory Filings (RNS).
2026-04-30 English
6-K - AC Immune SA (0001651625) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It announces an amendment to a license and collaboration agreement with Eli Lilly and Company, including financial terms such as upfront and milestone payments. The document includes a press release as an exhibit and signatures from the CEO and CFO. The length is 2647 characters, which is relatively short and primarily serves as an announcement rather than a full financial report. It does not contain detailed financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often include announcements and compliance documents.
2026-04-07 English
3 - AC Immune SA (0001651625) (Issuer)
Director's Dealing
2026-03-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.